Arbutus Biopharma Corporation Company Profile (NASDAQ:ABUS)

Arbutus Biopharma Corporation trades on the NASDAQ under the ticker symbol "ABUS."

Arbutus Biopharma Corporation (NASDAQ:ABUS) announced its quarterly earnings data on Thursday, November, 5th. The company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.31) by $0.11. The business earned $4.10 million during the quarter, compared to analysts' expectations of $3.37 million. View Arbutus Biopharma Corporation's Earnings History.

Arbutus Biopharma Corporation is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Arbutus Biopharma Corporation.

5 analysts have issued 1-year price targets for Arbutus Biopharma Corporation's shares. Their predictions range from $6.00 to $32.00. On average, they anticipate Arbutus Biopharma Corporation's stock price to reach $15.67 in the next year. View Analyst Ratings for Arbutus Biopharma Corporation.

Here are some recent quotes from research analysts about Arbutus Biopharma Corporation stock:

• 1. According to Zacks Investment Research, "Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC. " (7/10/2017)
• 2. Wedbush analysts commented, "We believe ABUS remains undervalued ahead of key clinical readouts in 2017 for its HBV pipeline candidates, a mid:17 readout of Alnylam's Ph 3 patisiran study in ATTR that could lead to a significant royalties to ABUS, and the potential for additional partnerships around its attractive LNP platform." (3/22/2017)

Arbutus Biopharma Corporation saw a drop in short interest during the month of August. As of August 31st, there was short interest totalling 418,041 shares, a drop of 24.0% from the August 15th total of 550,388 shares. Based on an average daily trading volume, of 88,979 shares, the days-to-cover ratio is presently 4.7 days. Approximately 1.2% of the shares of the company are short sold.

Some companies that are related to Arbutus Biopharma Corporation include WAVE Life Sciences (WVE), Abeona Therapeutics (ABEO), ImmunoGen (IMGN), AC Immune SA (ACIU), ANI Pharmaceuticals (ANIP), Inovio Pharmaceuticals (INO), Celyad SA (CYAD), Kala Pharmaceuticals (KALA), PDL BioPharma (PDLI), Adamas Pharmaceuticals (ADMS), Voyager Therapeutics (VYGR), Mesoblast Limited (MESO), Cara Therapeutics (CARA), Agenus (AGEN), Celldex Therapeutics (CLDX), Corvus Pharmaceuticals (CRVS), Novavax (NVAX) and Idera Pharmaceuticals (IDRA).

Arbutus Biopharma Corporation's management team includes the folowing people:

• Vivek Ramaswamy, Chairman of the Board
• Mark J. Murray Ph.D., President, Chief Executive Officer, Director
• Bruce G. Cousins, Chief Financial Officer, Executive Vice President
• Elizabeth Howard, Executive Vice President, General Counsel
• Peter Lutwyche Ph.D., Chief Technology Officer
• Michael Joseph Sofia, Chief Scientific Officer
• William Thomas Symonds III, Chief Development Officer, Director
• Michael J. Abrams Ph.D., Managing Director - Non-HBV Assets
• Patrick T. Higgins, Chief Business Officer
• Daniel D. Burgess, Director

Arbutus Biopharma Corporation's stock is owned by a number of of institutional and retail investors. Top institutional investors include Bank of Montreal Can (1.59%), AXA (1.42%), K2 Principal Fund L.P. (0.68%), Victory Capital Management Inc. (0.24%), Goldman Sachs Group Inc. (0.17%) and OxFORD Asset Management LLP (0.15%). View Institutional Ownership Trends for Arbutus Biopharma Corporation.

Arbutus Biopharma Corporation's stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., K2 Principal Fund L.P. and AXA. View Insider Buying and Selling for Arbutus Biopharma Corporation.

Arbutus Biopharma Corporation's stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., OxFORD Asset Management LLP, Bank of Montreal Can and Vanguard Group Inc.. View Insider Buying and Selling for Arbutus Biopharma Corporation.

Shares of Arbutus Biopharma Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Arbutus Biopharma Corporation stock can currently be purchased for approximately $6.55.